We are live on
!
Find out more
ED
Exane Derivatives Portfolio holdings
AUM
$174M
1-Year Est. Return
7.84%
This Fund
S&P 500
This Quarter
Est. Return
+23.79%
1 Year Est. Return
-7.84%
3 Year Est. Return
+42.72%
5 Year Est. Return
+56.28%
10 Year Est. Return
–
AUM
$340M
AUM Growth
-$5.31M
(-1.5%)
Cap. Flow
-$33M
Cap. Flow
% of AUM
-9.71%
Top 10 Holdings %
Top 10 Hldgs %
23.05%
Holding
889
New
138
Increased
211
Reduced
255
Closed
64
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Stellantis
STLA
|
+$10.1M |
| 2 |
Vale
VALE
|
+$2.39M |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$2.33M |
| 4 |
Coca-Cola
KO
|
+$2.2M |
| 5 |
Wells Fargo
WFC
|
+$1.58M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street Energy Select Sector SPDR ETF
XLE
|
+$13.6M |
| 2 |
iShares MSCI Turkey ETF
TUR
|
+$7.85M |
| 3 |
iShares MSCI Taiwan ETF
EWT
|
+$6.97M |
| 4 |
Logitech
LOGI
|
+$5.93M |
| 5 |
UBS Group
UBS
|
+$5.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 15.45% |
| 2 | Technology | 13.37% |
| 3 | Healthcare | 13.11% |
| 4 | Financials | 10.95% |
| 5 | Communication Services | 7.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NGM
326
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $176K | 0.05% |
+5,819
| New | +$127K |
|
327
State Street Industrial Select Sector SPDR ETF
XLI
$32.5B
| $174K | 0.05% |
+1,970
| New | +$166K |
|
328
iShares MSCI Emerging Markets Asia ETF
EEMA
$826M
| $173K | 0.05% |
+1,976
| New | +$161K |
|
329
Amgen
AMGN
$209B
| $172K | 0.05% |
749
+226
| +43% | +$52.1K |
|
|
BSL
330
Blackstone Senior Floating Rate 2027 Term Fund
BSL
$169M
| $171K | 0.05% |
12,000
| – | – |
|
331
Trane Technologies
TT
$97.3B
| $169K | 0.05% |
+1,164
| New | +$161K |
|
332
Duke Energy
DUK
$98.4B
| $169K | 0.05% |
1,842
+260
| +16% | +$24.1K |
|
333
Regeneron Pharmaceuticals
REGN
$77.4B
| $168K | 0.05% |
348
+155
| +80% | +$83.7K |
|
|
IGMS
334
DELISTED
IGM Biosciences
IGMS
| $165K | 0.05% |
1,870
| – | – |
|
335
BioMarin Pharmaceuticals
BMRN
$11.7B
| $163K | 0.05% |
1,858
+1,130
| +155% | +$89.6K |
|
336
iShares Global Healthcare ETF
IXJ
$4.11B
| $161K | 0.05% |
2,107
-119
| -5% | -$8.76K |
|
337
ProShares Ultra S&P500
SSO
$7.76B
| $160K | 0.05% |
7,000
+2,080
| +42% | +$42.7K |
|
338
Cencora
COR
$60.7B
| $159K | 0.05% |
1,624
-14,196
| -90% | -$1.42M |
|
339
Spotify
SPOT
$107B
| $157K | 0.05% |
500
+494
| +8,233% | +$139K |
|
340
Zymeworks
ZYME
$1.67B
| $156K | 0.05% |
3,301
+632
| +24% | +$29.4K |
|
|
DSL
341
DoubleLine Income Solutions Fund
DSL
$1.23B
| $154K | 0.05% |
9,300
| – | – |
|
342
Okta
OKTA
$24.4B
| $153K | 0.04% |
+600
| New | +$143K |
|
|
PPLT
343
abrdn Physical Platinum Shares ETF
PPLT
$1.89B
| $151K | 0.04% |
15,000
-7,020
| -32% | -$61.9K |
|
|
344
Logitech
LOGI
$14.6B
| $149K | 0.04% |
1,523
-68,714
| -98% | -$5.93M |
|
345
Home Depot
HD
$332B
| $148K | 0.04% |
559
+98
| +21% | +$26.9K |
|
346
iShares Global REIT ETF
REET
$5.12B
| $143K | 0.04% |
5,995
| – | – |
|
347
Aurinia Pharmaceuticals
AUPH
$1.93B
| $140K | 0.04% |
10,128
+5,028
| +99% | +$73.2K |
|
348
Kiniksa Pharmaceuticals
KNSA
$6.1B
| $139K | 0.04% |
7,863
+2,580
| +49% | +$45.3K |
|
349
Incyte
INCY
$24.9B
| $137K | 0.04% |
1,577
+259
| +20% | +$22.4K |
|
350
Iron Mountain
IRM
$37.1B
| $134K | 0.04% |
4,538
+202
| +5% | +$5.61K |
|
Similar funds
PC
TWMP
LPWM
ACM
HWIS
LWM
EW
GDWAM
Exane Derivatives's Q4 2020 Portfolio in Review
As of Q4 2020, Exane Derivatives held 889 positions worth $340M, down 1.5% from $345M the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Exane Derivatives withdrew a net $33M in Q4 2020, closing 64 positions and reducing 255 holdings. Its most notable exit was ProShares S&P 500 Dividend Aristocrats ETF, an estimated $2.55M position sold in full.
By sector, the portfolio is most concentrated in Consumer Discretionary at 15% of assets, up from 8.8% a quarter earlier, followed by Technology and Healthcare.
Against the trend, Exane Derivatives opened a new position in Vale worth $3.01M.
- Exane Derivatives's largest Q4 2020 buy was Vale: 179,430 shares worth $3.01M.
- Exane Derivatives added most to Stellantis in Q4 2020, an estimated $10.1M increase.
- Exane Derivatives's biggest Q4 2020 reduction was State Street Energy Select Sector SPDR ETF, cutting an estimated $13.6M.
- Exane Derivatives fully exited ProShares S&P 500 Dividend Aristocrats ETF in Q4 2020, selling an estimated $2.55M.
- Exane Derivatives's ten largest holdings make up 23% of its $340M portfolio in Q4 2020.
- Exane Derivatives opened 138 new positions and closed 64 in Q4 2020.
- Exane Derivatives's portfolio value fell 1.5% quarter-over-quarter to $340M.
Based on Exane Derivatives's 13F filing for Q4 2020, filed 27 Jan 2021.